Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;17(10):e799-801.
doi: 10.1016/j.ijid.2013.02.030. Epub 2013 Jun 15.

Ribavirin is not effective against Crimean-Congo hemorrhagic fever: observations from the Turkish experience

Bahadır Ceylan  1 , Aylin Calıca, Oznur Ak, Yasemin Akkoyunlu, Vedat Turhan
Affiliations

Ribavirin is not effective against Crimean-Congo hemorrhagic fever: observations from the Turkish experience

Bahadır Ceylan et al. Int J Infect Dis. 2013 Oct.

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is a viral infection associated with a high mortality rate. Ribavirin is the only drug used in the treatment of this disease. Studies investigating the effectiveness of ribavirin in CCHF have been retrospective and to date have included only a small number of cases. In recent years, due to climate changes, the number of cases of CCHF in Turkey has increased, and experience in the treatment of CCHF has improved. Several studies have evaluated the efficacy of ribavirin in Turkey, including one randomized controlled trial and two studies with a large number of cases. In these studies, ribavirin therapy was not shown to decrease mortality rates; the mortality rate was 2-9% in patients treated with ribavirin and 5.6-11% in those who were not treated with this drug. These findings suggest that patients with CCHF should be followed with supportive care only until randomized controlled trials with larger groups have been conducted.

Keywords: Crimean-Congo hemorrhagic fever; Ribavirin.

PubMed Disclaimer

Comment in

References

    1. Ergonul O. Crimean-Congo haemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol. 2012;2:215–220. - PubMed
    1. Doganci L. New insights on the bleeding disorders in CCHF. J Infect. 2007;55:379–381. - PubMed
    1. Chen J.P., Cosgriff T.M. Haemorrhagic fever virus induced changes in hemostasis and vascular biology. Blood Coagul Fibrinolysis. 2000;11:461–483. - PubMed
    1. Peters C.J., Zaki S.R. Role of the endothelium in viral hemorrhagic fevers. Crit Care Med. 2002;30:268–273. - PubMed
    1. Ergonul O., Tuncbilek S., Baykam N., Celikbas A., Dokuzoguz B. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo haemorrhagic fever. J Infect Dis. 2006;193:941–944. - PubMed

MeSH terms

LinkOut - more resources